Lipocine (NASDAQ:LPCN) Posts Quarterly Earnings Results

Lipocine (NASDAQ:LPCN) announced its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.08, FiscalAI reports. The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.21 million. Lipocine had a negative net margin of 571.18% and a negative return on equity of 66.70%.

Lipocine Stock Performance

LPCN stock traded up $0.10 on Wednesday, reaching $2.23. The company’s stock had a trading volume of 47,603 shares, compared to its average volume of 228,086. Lipocine has a 12-month low of $1.81 and a 12-month high of $12.37. The business has a fifty day simple moving average of $2.28 and a two-hundred day simple moving average of $4.81. The firm has a market cap of $18.38 million, a PE ratio of -1.19 and a beta of 0.46.

Hedge Funds Weigh In On Lipocine

A number of hedge funds have recently bought and sold shares of the company. Squadron Capital Management LLC bought a new stake in shares of Lipocine in the fourth quarter worth approximately $4,256,000. Diadema Partners LP bought a new stake in Lipocine during the 4th quarter valued at approximately $2,095,000. Ikarian Capital LLC purchased a new stake in Lipocine in the 4th quarter worth $1,602,000. Boothbay Fund Management LLC bought a new stake in Lipocine in the 4th quarter worth approximately $441,000. Finally, Citadel Advisors LLC bought a new position in Lipocine during the third quarter valued at $41,000. Institutional investors own 9.11% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on LPCN shares. Wall Street Zen raised shares of Lipocine from a “sell” rating to a “hold” rating in a research note on Saturday, July 18th. Weiss Ratings downgraded Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 18th. One analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $15.00.

About Lipocine

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.